Genoskin Secures $8.7M Series A to Advance Human Skin Biology

Genoskin, a specialist in skin biology and immunology, has announced it has successfully raised $8,700,000 in a new funding round from investors. This significant capital infusion is set to bolster the company's mission to provide authentic, human-relevant data for research and drug development across various industries. The company offers expertise in skin biology and immunology to support research and drug development initiatives. Its core mission involves generating reliable human data before regulatory studies for therapeutics, vaccines, medical devices, cosmetics, and chemicals. Genoskin achieves this by utilizing donated human skin, which it preserves for up to seven days post-surgery using its proprietary patented technology. This allows for comprehensive testing across all cell types and skin structures, distinguishing its platforms from animal or engineered models by providing highly relevant human data. Its advanced assays, including imaging techniques and next-generation sequencing, combined with deep scientific expertise, aim to equip clients with precise data to accelerate their projects. This funding round represents a pivotal moment for Genoskin, enabling it to further scale its innovative approach. The company plans to strategically deploy the newly secured capital to accelerate its growth initiatives, including expanding its operational capacity and enhancing its cutting-edge research and development platforms. This investment will also support the ongoing refinement of its unique technology, ensuring continued leadership in human-relevant preclinical testing. With this substantial investment, Genoskin is poised to solidify its market position and extend its reach within the pharmaceutical, cosmetic, and chemical industries. The company looks forward to continuing to empower its clients with high-fidelity human data, driving forward the development of safer and more effective products globally.